Overview

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

Status:
Active, not recruiting
Trial end date:
2020-11-02
Target enrollment:
Participant gender:
Summary
Single ascending doses of AP-101 will be administered by intravenous (IV) infusion
Phase:
Phase 1
Details
Lead Sponsor:
AL-S Pharma